Healthcare firms dominated last week’s 10 top penny stocks to buy, accounting for nearly half of the list.
In fact, the best healthcare penny stock, CordMedix Inc. (NYSE: CRMD), locked in a 44% gain on news that the company is likely to achieve nearly 8% earnings-per-share growth by the end of the year.
While we can’t cash in on CordMedix’s gains now, we can use data from last week’s top penny stocks to determine which penny stocks could jump next.
After looking at last week’s top penny stocks, we’ll show a penny stock with serious breakout potential. You won’t want to miss this…
|Penny Stock||Sector||Current Share Price||Last Week’s Gain|
|Orchids Paper Products Co. (NYSE: TIS)||Consumer Goods||$1.57||88.05%|
|Dixie Group Inc. (NASDAQ: DXYN)||Industrial Goods||$1.44||56.70%|
|Zedge Inc. (NYSE: ZDGE)||Technology||$2.80||53.34%|
|Dogness International Corp. (NASDAQ: DOGZ)||Consumer Goods||$3.12||50.44%|
|CorMedix Inc. (NYSE: CRMD)||Healthcare||$1.30||44.07%|
|MiMedx Group Inc. (OTCMKTS: MDXG)||Healthcare||$3.38||31.95%|
|Bio-Path Holdings Inc. (NASDAQ: BPTH)||Healthcare||$0.59||29.50%|
|Real Goods Solar Inc. (NASDAQ: RGSE)||Industrial Goods||$0.71||28.30%|
|AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX)||Healthcare||$3.57||27.82%|
|CBAK Energy Technology Inc. (NASDAQ: CBAK)||Technology||$0.73||22.81%|
Most of the healthcare companies in last week’s top penny stocks are biopharmaceutical firms developing cutting-edge treatments that, if successful, will be worth a fortune.
You see, Americans’ prescription drug use has risen nearly 100% over the last 20 years. In fact, Americans filled nearly 4.5 billion drug prescriptions last year.
Critical: A breakthrough technology could disrupt every major industry, and one tiny company is at the center of it all. Its stock is trading for less than $10 now, but could deliver a 471.9% gain for early investors. Learn more…
And this growth isn’t slowing down anytime soon. The industry is expected to expand by an additional 5% in 2019. That’s an additional 225 million prescriptions.
It’s a spectacular profit opportunity. However, with over 2,800 penny stocks trading on the major exchanges, it can be difficult to find the one penny stock that’s going to benefit the most from explosive growth in the pharmaceutical industry.
That’s why we’ve identified one penny stock that’s perfectly positioned to cash in on this wave.
It’s a little-known pharmaceutical firm developing revolutionary treatments for an array of medical maladies.
It has the potential to skyrocket an incredible 950%.
And it’s only trading for $0.54 a share…
The Top Penny Stock to Buy Right Now
EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) is a Massachusetts-based pharmaceutical company that develops solutions to treat eye disorders and diseases.
One of the company’s most exciting developments is an Ocular Bandage Gel that is applied topically via an eye drop. This product is currently undergoing clinical trials for post-surgical use as well as for use in the treatment of certain eye injuries.
EyeGate has licensing agreements with several schools and other companies, such as the University of Miami School of Medicine, the University of Utah Research Foundation, and Valeant Pharmaceuticals International Inc.
In April, EyeGate announced an $11.25 million public offering of more than 35 million shares of common stock at an offering price of $0.32. This sent share prices soaring from $0.31 to $0.64 – an increase of nearly 100%.
But even bigger gains could be coming soon, especially if its latest treatment is a hit.
Analysts have given EyeGate stock a price target of $6.00 a share – a staggering 950% increase over today’s price of $0.54.
This Company Could Be Holding the Biggest Tech Breakthrough of the DECADE
Global Market Insights sees this market worth over $80 billion by 2024.
Technology giants like Apple and Microsoft are making huge multimillion-dollar investments in this space.
Defense contractors and the U.S. military are using this market’s technology to give soldiers a competitive “advantage at sea, land, and air.”
And one company is at the center of it all. See it here…
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2018 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.
This post is from MoneyMorning. We encourage our readers to continue reading the full article from the original source here.